Study of ALE.C04 in Patients With Head and Neck Cancer
Status:
Recruiting
Trial end date:
2028-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety profile of ALE.C04 monotherapy and in
combination with pembrolizumab, to characterize pharmacokinetics profile of ALE.C04,
recommended Phase II dose (RP2D) for ALE.C04 in combination with pembrolizumab and as
monotherapy and to assess anti-tumor activity of ALE.C04 monotherapy and in combination with
pembrolizumab in patients with Head and Neck Cancer.